Updates to the Management of Patients with Relapsed/Refractory Indolent B-Cell Lymphomas
In the last decade, the advent of novel targeted therapies has resulted in a major paradigm shift in the management of patients with relapsed/refractory follicular lymphoma and marginal zone lymphomas. Accurate diagnosis of the indolent lymphoma subtype, appropriate patient selection, and effective management of the unique spectrum of adverse events associated with targeted therapies should be an integral part of management of patients with relapsed/refractory disease. Even in the era of targeted therapies, patients with relapsed or progressive disease after first-line therapy will benefit from a second period of observation until they have indications for retreatment. Oncologists and hematologists need to maintain high awareness of the recently approved targeted therapies and the precise indications for their use so that these can be incorporated in routine clinical practice in the appropriate patient population.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Summarize the data from clinical trials on the use of targeted therapies for the treatment of patients with relapsed or refractory follicular lymphomas.
- Review the safety and efficacy of novel treatment options for relapsed or refractory marginal zone lymphomas.
- Develop individualized treatment plans integrating novel treatment approaches for the management of patients with relapsed/refractory follicular lymphomas or marginal zone lymphomas.
Ann S. LaCasce, MD, MMSc
Dana-Farber Cancer Institute
Ariela Noy, MD
Memorial Sloan Kettering Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Presenting Faculty
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Ann S. LaCasce, MD, MMSc
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Ariela Noy, MD
ADC Therapeutics: Scientific Advisor
Epizyme: Scientific Advisor
EUSA: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
MorphoSys AG: Scientific Advisor
Pharmacyclics Research Funding: Honoraria
Rafael Pharma: Grant/Research Support
TG Therapeutics, Inc.: Scientific Advisor
Moderator
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Nathan Fowler, MD
Celgene Corporation: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
TG Therapeutics, Inc.: Consulting Fee
Roche Laboratories, Inc. Grant/Research Support; Consulting Fee
NCCN Staff Disclosures
The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support
Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary
None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour, 1.0 of which are pharmacotherapeutic contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-054-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 1, 2023. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing